ArcheMedX Releases Largest Confidence-Based Assessment Dataset in CNS Clinical Research at CNS Summit 2025
Charlottesville, VA — October 29, 2025
ArcheMedX, a leader in clinical trial readiness and behavioral science, has released analyses of the largest known dataset of Confidence-Based Assessment (CBA) data in the CNS research space. Initial findings will be presented during CNS Summit 2025.
During Poster Session #6, ArcheMedX will share insights from more than 5 million question responses submitted by over 400,000 CNS-treating clinicians trained through the Ready platform. This unprecedented dataset reveals widespread gaps in clinical understanding that can compromise protocol execution and introduce avoidable trial risk. The analysis demonstrates how targeted, role-specific training can reduce these risks and supports ICH E6(R3) guidance on proactive quality management and team readiness.
“This dataset shows what’s possible when we rethink how training is delivered and measured,” said Joel Selzer, CEO of ArcheMedX. “Trial sponsors now have the ability to not just track participation, but to truly understand whether clinical teams are ready to perform when it matters most.”
Confidence-Based Assessment: A Smarter Way to Measure Readiness
Unlike traditional assessments that only track correctness or completion, CBA introduces a second dimension: confidence. By pairing each knowledge question with a confidence rating, CBA reveals whether a learner has mastered the topic—or if they are misinformed, unsure, or guessing. These indicators are critical to predicting performance in real-world study conditions.
In the CNS dataset, nearly 1 in 5 learners were found to be guessing during the pre-assessments. This hidden gap represents a material risk for trial sponsors. If left unaddressed, it could result in activating sites that do not fully understand the protocol or how delegated responsibilities should be executed.
Following training delivered through the Ready platform, guessing was reduced by 76% and Mastery (correct and confident responses) increased by 177%. These gains provide sponsors with greater confidence in the site’s ability to properly conduct the study and represent a significant reduction in trial risk.
By aligning education with cognitive and behavioral readiness, CBA transforms training from a check-the-box exercise into a measurable driver of quality and oversight.
“Confidence is not just a feeling—it’s the bridge between knowledge and behavior,” said Dr. Brian McGowan, co-founder and Chief Learning Officer of ArcheMedX. “CBA helps sponsors identify whether teams truly understand what they’ve learned and are ready to apply it in the field.”
CNS Trials: High Stakes Require High Readiness
CNS trials pose unique challenges—from cognitive scales and subjective endpoints to complex eligibility criteria and vulnerable patient populations. Trial success depends on well-prepared clinicians and raters.
The Ready platform transforms static protocols, scales, and assessments into interactive, role-specific learning experiences. This approach enables sponsors to:
- Shorten site initiation timelines
- Reduce protocol deviations
- Improve patient selection and retention
- Ensure data consistency and minimize bias
- Streamline ongoing remediation and oversight
These capabilities are especially critical for CNS trials, where variability in execution can compromise data integrity and patient safety.
See the Findings at CNS Summit 2025
Poster Session #6
Monday and Tuesday, November 3–4
5:00–7:00 PM
Encore Boston Harbor
ArcheMedX will also host invitation-only networking dinners with clinical trial leaders on both evenings. To request a seat or schedule a 1:1 meeting, visit: https://www.info.archemedx.com/cns25
About ArcheMedX
ArcheMedX helps life sciences organizations modernize study training and accelerate the adoption of novel treatments through its Ready platform. By applying principles of behavioral science and Confidence-Based Assessment, ArcheMedX enables sponsors and CROs to uncover hidden gaps, reduce study risk, and ensure every trial team is truly prepared to perform. The platform is trusted by 21 of the top 25 global pharmaceutical companies, leading CROs, and fast-growing biotechs.
Learn more at: www.archemedx.com
